Search our Database of Scientific Publications and Authors

I’m looking for a

    6109 results match your criteria Archivos espanoles de urologia[Journal]

    1 OF 123

    Is retrograde intrarenal surgery replacing percutaneous nephrolithotomy as surgical treatment of stone disease: Our clinical experience.
    Arch Esp Urol 2018 Jun;71(5):506-511
    Department of Urology. Kecioren Research and Training Hospital. Ankara. Turkey.
    Objective: Urolithiasis prevalence is 2-20% according to different geographic characteristics in different populations. In this study, we aimed to present the distribution of operation numbers for both percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS) in terms of age and stone size in order to reveal the changes over the years.

    Method: Between January 2010 and March 2016, 1814 patients were operated for the treatment of renal stones. Read More

    [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.]
    Arch Esp Urol 2018 Jun;71(5):502-505
    Servicio de Urología. Hospital de Poniente. El Ejido. Almería. España.
    The transdermal route for administration of anticholinergic drugs can provide efficacy with less systemic adverse effects. The transdermal oxybutynin patch (OXYTDS) offers advantages over oral administration for patients treated for Overactive bladder (OAB) syndrome. The limited evidence on the OXY-TDS patch application areas of the skin, makes difficult counseling patients who require a change to skin zones other than those recommended by the manufacturer. Read More

    [Endoscopically treated vesicoureteral reflux: Evolution of the recurrences.]
    Arch Esp Urol 2018 Jun;71(5):495-501
    Hospital Universitario 12 de Octubre. Madrid. España.
    Objectives: In recent years, different studies have mentioned the recurrence of vesicoureteral reflux (VUR) endoscopically resolved, an exceptional event after open surgery. The aim of this study is to describe the evolution of the cases of recurrence identified in our center to assess the importance of this event.

    Method: We have identified the cases of VUR that recurred after successful endoscopic treatment in our anesdepartment. Read More

    [Usefulness of cold ureteral biopsy during radical cystectomy as a predictor of recurrence risk: Review of our series.]
    Arch Esp Urol 2018 Jun;71(5):486-494
    Servicio de Urología. Hospital Universitario Central de Asturias. Oviedo. Asturias. España.
    Objectives: To evaluate the association of positive margins in the intraoperative biopsy during radical cystectomy (RC) with the risk of recurrence in the uretero-ileal anastomosis or upper urinary tract (UUT), and identify potential risk factors for positive ureteral margins.

    Methods: A retrospective, descriptive study was performed in patients treated with radical cystectomy due to transitional cell carcinoma (TCC), who underwent a cold biopsy of the ureteral margin at the time of cystectomy. A descriptive analysis and frequency distribution was performed. Read More

    [Impact of tumor diameter on prognosis in patients with renal cancer stage pT3a.]
    Arch Esp Urol 2018 Jun;71(5):480-485
    Centro Urológico Profesor Bengió. Córdoba. Argentina.
    Objective: To determine the prognostic impact that tumor size has in patients with pathological renal cancer stage pT3a.

    Methods: Retrospective, descriptive study evaluating 261 patients diagnosed with renal cancer pathological stage pT1-3aN0M0 between 1995 and 2013. Clinical and pathological characteristics were evaluated in each group. Read More

    [Kidney cancer stage pT3a: Fat invasion versus renal vein invasion.]
    Arch Esp Urol 2018 Jun;71(5):474-479
    Servicio de Urología. Hospital Universitario La Paz. Madrid. España.
    Objective: We discuss the influence that involvement of fat (perirenal, sinus) and vascular structures (renal vein, segmental veins) have on cancer-specific mortality (CSM) rates in renal cancer.

    Methods: We conducted a retrospective analysis of 140 stage pT3a kidney tumors (114 clear cell, 9 type I papillary, 6 type II papillary, 11 chromophobe) surgically treated between 1997 and 2015. We conducted a cancer-specific survival study (Kaplan Meier) and a univariate and multivariate analysis of the variables: perirenal fat invasion, sinus fat invasion, renal vein invasion, segmental vein invasion and Fuhrman grade. Read More

    [Evolution of radical prostatectomy in the Autonomous Community of Madrid.]
    Arch Esp Urol 2018 Jun;71(5):466-473
    Servicio de Urología. Hospital Universitario La Paz. Madrid. España.Instituto de Investigación Hospital Universitario la Paz (IdiPAZ).
    Objectives: To analyze the implantation of laparoscopic radical prostatectomy (LRP) in the Public Health System in the Autonomous Community of Madrid (CAM) and to investigate the different results between laparoscopic and open radical prostatectomy.

    Methods: We performed a retrospective analysis over a database containing data from 25 hospitals in CAM. We chose 8225 patients treated by radical prostatectomy (open or laparoscopic). Read More

    [Malpractice in Urology: lessons of clinical and legal safety.]
    Arch Esp Urol 2018 Jun;71(5):459-465
    Servicio de Responsabilidad Profesional. Area de Praxis. Colegio de Médicos de Barcelona. Consejo de Colegios de Médicos de Cataluña. Barcelona. España.Unidad de Medicina Legal y Forense. Departamento de Salud Pública. Facultad de Medicina. Universidad de Barcelona. Barcelona. España.
    Objectives: Data about urology malpractice claims in our environment are scarce and should be considered a potential opportunity to "learn from errors".

    Methods: We analyzed every claim for alleged malpractice in Urology managed by the Council of Medical Colleges of Catalonia between 1990 and 2012, and specifically evaluated the clinical and medicolegal features of those cases with medical professional responsibility.

    Results: We identified 182 cases in 22 years, but only the 25,74%showed professional liability. Read More

    [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.]
    Arch Esp Urol 2018 May;71(4):453-457
    Servicio de Urologí a. Complejo Hospitalario Universitario A Coruña. (CHUAC). España.
    Bacilus Calmette-Guerin (BCG) administered intravesical is an effective therapy in non muscle invasive bladder cancer (NMIBC), but it presents limitations regarding recurrence and toxicity. For years, many case series have been published where sequential therapy with BCG and Mitomycin C (MMC) was tried. In this article, we perform a review of the data supplied by these articles with the aim to determine the safety and efficacy of combination, and what is the group of patients it should be indicated. Read More

    Heat-targeted drug delivery: A promising approach for organsparing treatment of bladder cancer.THERMODOX®.
    Arch Esp Urol 2018 May;71(4):447-452
    División de Urología. Duke University Medical Center. Durham. NC. USA.
    Disease recurrence and progression remain as significant challenges for the management of non-muscle invasive bladder cancer (NMIBC). In recent years, novel drugs and delivery systems have been investigated as strategies to reduce recurrence, progression and mortality. In this review, we focus on the role of intravesical hyperthermic chemotherapy and discuss a novel approach involving a heat-activated drug delivery system (ThermoDox®) that enables local accumulation of systemic chemotherapy. Read More

    Neoadjuvant chemohyperthermia: Our experience after 10 years.
    Arch Esp Urol 2018 May;71(4):438-446
    Servicio de Urología. Hospital Comarcal de Monforte. Monforte-Lugo. España.
    Neoadjuvant chemohyperthermia (QHT) with MMC has demonstrated its efficacy in NMIBC both in the level of complete response at the time of TURBT and reduction of recurrences after several years of follow up. We present our experience with this treatment.

    Methods: We performed a case control study in a group of 104 patients with middle-high risk NMIBC. Read More

    Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer.
    Arch Esp Urol 2018 May;71(4):426-437
    Servicio de Urología. Hospital Comarcal de Monforte. Monforte-Lugo. España.
    Objectives: The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge. Hyperthermia (HT) combined with intravesical chemotherapy is used to enhance the effects of chemotherapy.

    Methods: A review of the publications was carried out to synthesize the adverse effects (AE) reported by the use of chemohyperthermia (QHT) with Mitomycin-C (MMC). Read More

    [Mitomycin C HIVEC. Update and results in high risk patients.]
    Arch Esp Urol 2018 May;71(4):417-425
    Unidad de Urooncología, Servicio de Urología. Hospital Universitario 12 de Octubre. Madrid. España.
    Adjuvant endovesical treatment is a research field in constant exploration with the aim to minimize the risk of recurrence and progression of non muscle invasive bladder tumors. Over the last years, the administration of chemotherapy in a chemo hyperthermia regimen has been added to the existing regimens. There are various systems for its administration, but this article focus on HIVEC (Hyperthermic IntraVEsical Chemotherapy) and its current status. Read More

    [EMDA with MMC. Critical review.]
    Arch Esp Urol 2018 May;71(4):409-416
    Ex-Jefe de Urología. Instituto Valenciano de Oncología. Miembro emérito del Instituto Valenciano de Oncología. Valencia. España.
    Two Phase II studies, three Phase III and one observational study seem to justify that EMDA-MMC is a real alternative in the treatment of patients with NMIBC, especially the high risk group. The phase III studies compare EMDA-MMC with passive diffusion MMC and BCG in patients with bladder TIS. They showed EMDA MMC superiority compared to passive diffusion MMC and similar to BCG in achieving complete response at 3 and 6 months. Read More

    [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.]
    Arch Esp Urol 2018 May;71(4):400-408
    Departmento de Urología. Radboud University Nijmegen Medical Centre. Nijmegen. The Netherlands.
    In an effort to decrease recurrence and progression rates in non-muscle-invasive bladder cancer (NMIBC), transurethral resection of a bladder tumor is followed by intravesical instillations using Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG). In spite of these adjuvant treatment modalities, recurrence and progression rates remain high. Because of these limitations of current standard therapy and the shortage of BCG, there is a search for alternative forms of treatment in NMIBC. Read More

    Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
    Arch Esp Urol 2018 May;71(4):393-399
    Servicio de Urología. Hospital Comarcal Monforte. Monforte. Lugo. España.
    Long-term survival for patients with advanced bladder cancer is precarious, with a 5-year survival of just 5% in metastatic cases. Normally, the binding of PD-L1 to PD-1 alters the immune activity by modulating it to inhibit autoimmune diseases or chronic inflammation. However, some cancers use this route to block the immune response of the patient and continue growing. Read More

    [New endovesical chemotherapy drugs and application vehicles.]
    Arch Esp Urol 2018 May;71(4):384-392
    Servicio de Urología. Hospital Universitario La Paz. Madrid. España.
    Urothelial bladder cancer is a very prevalent disease. At the time of diagnosis 70-80% of the cases present as non muscle invasive tumors. These tumors present a high recurrence and progression rates despite intravesical treatment with Bacille Calmette-Guerin and mitomycin C. Read More

    [Immediate post TURBT MMC instillation.]
    Arch Esp Urol 2018 May;71(4):376-383
    Servicio de Urología. Fundación Instituto Valenciano de Oncología. Valencia. España.
    Mitomycin C is an antitumor alkylating antibiotic agent that inhibits DNA synthesis extensively used as intravesical chemotherapy agent in the adjuvant treatment of urothelial carcinoma. Its clinical efficacy is the context of single early postoperative instillation was demonstrated by Toley et al. in 1988. Read More

    [Mechanism of action of intravesical BCG. Biological bases and clinical applicability.]
    Arch Esp Urol 2018 May;71(4):358-375
    Servicio y Catedra de Urología. Hospital Universitario "Puerta de Hierro - Majadahonda" Universidad Autónoma de Madrid. Facultad de Medicina. Madrid. España.
    The therapeutic approaches developed around immune system modulation find the therapeutic contribution of intravesical Bacillus Calmette Guerin (BCG) for transitional cell bladder cancer an unquestionable example as a proof of concept of antitumor immunotherapy since more than 30 years ago. Intravesical immunotherapy for urothelial carcinomas is considered with periodic intravesical instillations schedules, and the one with longer historic development and wider diffusion is BCG in the form of suspension. BCG is a unique strain obtained from Mycobacterium bovis at the end of the first third of the XX century and represents the historically most successful immunotherapeutic modality of all tumors with a high level body of evidence. Read More

    [BCG therapy in NMIBC: How much and for how long?.]
    Arch Esp Urol 2018 May;71(4):349-357
    Urología Clínica Bilbao. Clínica IMQ Zorrotzaurre. Bilbao. Bizkaia. España.
    Bladder cancer is the 9th most prevalent cancer in the world. It is divided into muscle invasive bladder cancer (MIBC) and non muscle invasive bladder cancer (NMIBC). Over 75% belong to the second group and it will be classified according to the risk of progression and recurrence. Read More

    BCG therapy in NMIBC: How much and for how long?.
    Arch Esp Urol 2018 May;71(4):342-348
    Departamento de Urología. Royal Surrey County Hospital. Egerton Road. Guildford. Surrey. UK.
    Since its introduction in 1976 Bacille Calmette- Guerin (BCG) has become the standard of care in high risk non-muscle-invasive bladder cancer (NMIBC). Despite more than 40 years of experience, we do not know the most optimal BCG dose to maximize effectiveness whilst minimizing side effects. There is universal agreement that an initial induction course of BCG should consist of 6 weekly instillations if tolerated. Read More

    [BCG and bladder cancer: Past, present and future.]
    Arch Esp Urol 2018 May;71(4):332-341
    Servicio de Uro-Oncologia. Fundació Puigvert. Barcelona. España.
    BCG has been used in the treatment of NMIBC for more than 40 years. Nevertheless, its exact working mechanisms have not been completely discovered. Clinical and basic research done over all these years has generated much information but it could be summarized in a few simple statements. Read More

    [Multidisciplinary teams in the treatment of prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):315-322
    Jefe de Servicio de Urología. Fundación Instituto Valenciano de Oncología. Valencia. España.
    In the last decade, prostate cancer management has dramatically evolved to such a complexity that different medical specialties have to participate for its optimization, even making necessary in many cases super specialization in every discipline for such aim. All Guidelines and every Scientific Association do recommend multidisciplinary teams for its management as a rule, but translation from multidisciplinary committees to daily assistance is heterogeneous and faces, many times, particular interests and conflicts between different specialties implying that objective information of all the therapeutic options does not reach the patient to enroll him in his own therapeutic pathway.This is an opinion paper reviewing the advantages of the multidisciplinary team daily work as a prolongation of the multidisciplinary committee decisions, relying in the literature to set the legal framework and recommendations to generate an operative and real model of multidisciplinary teamwork for the benefit of both patient and all professionals involved in prostate cancer management. Read More

    [Advanced prostate cancer and quality of life.]
    Arch Esp Urol 2018 Mar;71(3):306-314
    Hospital Universitario de Salamanca. Salamanca. España. Grupo de Investigación Traslacional de Urología GITUR-IBSA. España.
    Objectives: The therapeutic range in advanced and castration resistant prostate cancer is widening. Therapies must offer real clinical efficacy, and they also should be acceptable and desirable for patients, specially in advanced disease. We analyze the value of quality of life analysis in patients with advanced prostate cancer. Read More

    [Radiotherapy for local disease in metastatic prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):298-305
    Oncología Radioterápica. Departamento de Oncología. Clínica Universidad de Navarra. Universidad de Navarra. Madrid. España.
    Objectives: We elaborate the bases and rationale for the application of multimodal extended treatment including local radiotherapy in patients with oligometastatic prostate cancer (omPCa). We performed a bibliographic review on the state of the art in this field and propose a therapeutic strategy that incorporates ablative radiotherapy of the primary tumor +/- oligometastatic lesions.

    Methods: We performed a comprehensive literature review consulting different sources that include data bases (Pubmed/Medline), and international treatment guidelines ((NCCN, NCI, EUA). Read More

    [Surgical treatment of local disease in metastatic prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):288-297
    Unidad de Uro-Oncología. Departamento de Urología. Fundació Puigvert. Universidad Autónoma de Barcelona. Barcelona. España.
    Objectives: Metastatic prostate cancer is a very heterogeneous disease with several treatment options. In some cases of oligometastatic disease, local treatment of the primary tumor complemented by metastasis directed therapy seems to improve oncological results. The objectives of this study are to define and understand oligometastatic prostate cancer, to show the usefulness and rationale of cytoreductive surgery in this scenario and to review all published studies about radical prostatectomy in patients with initially metastatic prostate cancer. Read More

    [The role of corticoids in the management of advanced prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):281-287
    Servicio de Oncología Médica. Hospital HM Madrid Sanchinarro. Centro Integral Oncológico Clara Campal (CIOCC). Madrid. España.
    Prostate cancer is the most frequent malignant tumor in males in developed countries and represents the second cause of cancer death. Over the last years, the number of treatments available for patients with advanced prostate cancer has improved significantly, achieving better disease control and notably better overall survival (1). Corticosteroids have been extensively used in the treatment of castration resistant prostate cancer due to their palliative benefits on symptoms secondary to their potent anti-inflammatory activity and their demonstrated antitumor activity. Read More

    [The role of chemotherapy in the treatment of hormone sensitive metastatic prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):276-280
    Departamento de Urología. Clínica Universidad de Navarra. Madrid. España.
    Objective: Several studies have assessed the role of adding chemotherapy to hormonal treatment for metastatic hormone-sensitive prostate cancer (MHSPC). The objective of this manuscript is to review these studies and to provide recommendations for the management of these patients.

    Methods: We identified published clinical trials comparing hormone blockade (HB) with HB plus docetaxel as first-line treatment of HSMPC and we analyzed their results in terms of efficacy and toxicity. Read More

    [Maximal androgen deprivation with abiraterone acetate in hormone sensitive prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):267-275
    Servicio de Urología. Hospital Universitario 12 de Octubre. Madrid. España.
    Objectives: The treatment of metastatic prostate cancer has remained unchanged for more than 70 years, based on androgen deprivation therapy (ADT). In 2015, following the CHAARTED and STAMPEDE trials, it was established that the addition of 6 cycles of docetaxel to ADT was associated with significantly increased survival. In June 2017, the LATITUDE trial and the G arm of the STAMPEDE trial showed that the addition of Abiraterone with Prednisone (5 mg/day) to ADT was also associated with a significant increase in survival in metastatic patients. Read More

    [Preventive management of bone disease in advanced prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):258-266
    Director Unidad Cáncer de Próstata. Servicio de Urología. Hospital General Universitario Morales Meseguer. Murcia. España.
    Objectives: Prostate cancer is linked to bone disease by two different entities. On one hand, androgen deprivation therapy (ADT) usually causes osteoporosis, on the other a great number of patients with advanced prostate cancer will present bone that condition not only their vital prognosis but also an important quality of life deterioration.

    Methods: We performed a bibliographic review on both the physiology and therapy of osteoporosis secondary to ADT and bone metastasis in prostatic neoplasias. Read More

    [Current status of androgen deprivation therapy in hormone-sensitive prostate cancer.]
    Arch Esp Urol 2018 Mar;71(3):247-257
    Servicio de Urología. Hospital Ramón y Cajal. Madrid. España.
    Objective: To analyze the current available evidence of androgen deprivation therapy in hormone-sensitive metastatic prostate cancer, focused on the relevance of suppressing circulating testosterone levels and its prognostic significance. To assess the optimal value of castration levels and PSA reduction under hormone treatment.

    Methods: We performed a bibliographic review through automatized search in the Pubmed bibliographic database and Clinical Key. Read More

    [Oligometastatic prostate cancer. concept and implications.]
    Arch Esp Urol 2018 Mar;71(3):239-246
    UGC Urología. Hospital Universitario Reina Sofía/IMIBIC. Córdoba. España.
    Oligometastatic prostate cancer has been proposed as an intermediate stage between localized and extensively disseminated disease. Oligometastatic disease is being diagnosed more frequently due to the advances in imaging tests. Nevertheless, there is no consensus definition yet of oligometastatic prostate cancer. Read More

    [Locally advanced prostate cancer. Definition, diagnosis and treatment.]
    Arch Esp Urol 2018 Mar;71(3):231-238
    Servicio de Urología. Hospital General Universitario Gregorio Marañón. Madrid. España.
    Prostate cancer is a disease that presents a wide spectrum from low aggressiveness localized to disseminated cancer. Locally advanced prostate cancer (LAPC) is a particularly difficult to manage phase of this spectrum.

    Objectives: We review the definition, diagnosis and treatment of this phase of the disease. Read More

    The effect of darbepoetin alfa on renal fibrosis in rats with acute unilateral ureteral obstruction.
    Arch Esp Urol 2018 Mar;71(2):212-221
    Department of Urology. Fatih Sultan Mehmet Research & Training Hospital. Istanbul. Turkey.
    Objectives: The most important treatment strategy for obstructive nephropathy is to protect renal tissue from the deleterious effects of fibrosis. Therefore, we sought to investigate the renoprotective effects of darbepoetin alfa on unilateral ureteral obstructions.

    Methods: We used 12 female and 12 male 3-monthold Wistar rats weighing between 250 and 350 g. Read More

    Pseudomyxoma peritonei: A case report and review of the literature.
    Arch Esp Urol 2018 Mar;71(2):208-211
    Department of Pathology. Hospital Universitario La Paz. Hospital General. Madrid. Spain.
    Objective: We present the case of a patient incidentally diagnosed with a pelvic mass next to the bladder. After surgical excision, definitive diagnosis was pseudomyxoma peritonei. We provide a concise review of the literature of this pathology. Read More

    [Small cell bladder carcinoma in age extremes: Report of two cases.]
    Arch Esp Urol 2018 Mar;71(2):204-207
    Hospital Universitario Virgen Macarena. Sevilla. España.
    Objective: We report 2 cases of small cell neuroendocrine carcinomas (CCP) of the urinary bladder in patients aged 37 and 80 years. CCP is a malignancy with poor prognosis. We review the literature, under the current WHO classification (2016). Read More

    Laparoscopic partial nephrectomy using the Simon clamp: our experience in 18 cases.
    Arch Esp Urol 2018 Mar;71(2):198-203
    Servicio de Urología. Hospital Alemán de Buenos Aires. Ciudad de Buenos Aires. Argentina.
    Objective: Kidney tumors represent 2- 3% of adult tumors. Partial nephrectomy is the standard of care for the treatment of localized tumors. Minimizing ischemia time is critical for postoperative renal function. Read More

    [Efficacy of lycopene intake in primary prevention of prostate cancer: a systematic review of the literature and meta-analysis.]
    Arch Esp Urol 2018 Mar;71(2):187-197
    Departamento de Urología. Hospital Universitario Fundación Santa Fe de Bogotá y Facultad de Medicina de la Universidad de los Andes. Bogotá D.C. Colombia.
    Objective: To evaluate the efficacy of lycopene intake in primary prevention of prostate cancer (PCa).

    Methods: A systematic search of the literature was conducted in March 2015 and the articles published between the years 1990-2015 were reviewed. The following search terms were used: prostate cancer, prostatic neoplasm, lycopene, prevention, effectiveness and efficacy (MeSH). Read More

    Application of ERAS (Enhanced Recovery After Surgery) and laparoscopic surgery in the management of patients with bladder cancer.
    Arch Esp Urol 2018 Mar;71(2):178-186
    Servicio de Anestesiología y Reanimación. Hospital Universitario La Paz. Madrid. España.
    Objective: The enhanced recovery after surgery program (ERAS) has become the base of perioperative management in various surgical specialties. However, limited data are available for radical cystectomy.

    Methods: We have analyzed 124 patients undergoing radical cystectomy. Read More

    [Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]
    Arch Esp Urol 2018 Mar;71(2):169-177
    Servicio de Urología. Hospital Universitario de Parla. Madrid. España.
    Objective: To compare the efficacy and safety of dietary supplement "Manosar®" composed of D-mannose (2 g), 24 h prolonged release, associated with Proanthocyanidin (PAC) (140 mg), ursolic acid (7.98 mg), A, C, and D vitamins and the oligoelement zinc, versus 240 mg of PAC in recurrent urinary tract infections (UTI), for a designed follow-up of 24 weeks, in women.

    Methods: A multicenter randomized experimental double-blind study was carried out. Read More

    Future of Urology training.
    Arch Esp Urol 2018 Jan;71(1):158-163
    Department of Urology. La Paz University Hospital. Madrid. Spain. European Association of Urology/Young Academics Urologists. Uro-Technology and communications working party. (ESUT-YAUwp). Arnhem. The Netherlands.
    Urology has become more complex through the years, as it comprises increasingly sophisticated medical and surgical technologies such as advanced medical tumour therapies, and endourological, laparoscopicand robotic surgical techniques. Training in urology starts during medical school and once a medical student chooses to specialize on it, becomes life-long. Becoming a good urologist requires a highly qualified education and sufficient experience. Read More

    [The role of social media in academic training in Urology. Adequate use.]
    Arch Esp Urol 2018 Jan;71(1):150-157
    European Association of Urology/Young Academics Urologists. Uro-Technology and communications working party. (ESUT-YAUwp). Arnhem. The Netherlands.Department of Urology. University of California. Irvine. California. USA.Life and Health Sciences Research Institute (ICVS). School of Medicine. University of Minho. Braga. Portugal. ICVS/3B's. PT Government Associate Laboratory. Braga. Guimarães. Portugal.
    Social media is characterized because all its services are participative. Users of 2.0 technologies can interact easily and openly with other people, share resources and communicate immediately and simultaneously. Read More

    [The urologist of the future and new technologies.]
    Arch Esp Urol 2018 Jan;71(1):142-149
    Servicio de Urología. Complejo Hospitalario Ruber. Madrid. España.
    The last 25 years have brought about revolutionary changes for medicine and in particular for urology: internet was only in its infancy, medical records were written on paper, searches for medical information were done in the hospital library, medical articles were photocopied and our relationship with patients only existed face to face. Social networks had not yet appeared and even Google did not exist. Just imagine what might happen during the next 25 years, we're going to see even more radical changes. Read More

    [On line learning in urologic surgery. The value of the 2.0 Web tools.]
    Arch Esp Urol 2018 Jan;71(1):134-141
    Servicio de Urología. Hospital Universitario Puerta de Hierro Majadahonda. Hospital Universitario Madrid Torrelodones. España.
    The field of Surgery is under the pressure of accelerated change where technological cycles get shorter and shorter, sometimes transformational. Learning and training have gotten a key role because learning curves for new techniques directly affect patient's safety and learning cycles are slower. The traditional learning model within the urology department is overwhelmed. Read More

    1 OF 123